Adial Pharmaceuticals Partners With Crown CRO to Begin Phase 3 Clinical Trials of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, and Crown CRO, a contract research organization based in Finland, today announced Crown’s engagement to manage Adial’s Phase 3 clinical trial for AD04 for the treatment of alcohol use disorder (AUD). The FDA approved protocol for this […]

Read More

Introducing our new Managing Director: Tarja Leikas

We at Crown CRO are pleased to introduce to you our new CEO, Tarja Leikas. Our long-term leader Päivi Itkonen, who is also one of our founders, steps into the position of Chief Commercial Officer and continues on Crown CRO board.

Read More

Nordic Conference on Pediatric Medicines

Crown CRO is proudly sponsoring the 2nd Nordic Conference on Pediatric Medicines, taking place in Helsinki on 21-22 May 2018. http://www.pif.fi/en/current-affairs/2nd-nordic-conference-pediatric-medicines-21-22-may-2018

Read More